A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.

ABSTRACT: The recent approval of ¹⁷⁷Lu PSMA-617 (Pluvicto^®) by the United States Food and Drug Administration (FDA) is the culmination of decades of work in advancing the field of targeted radionuclide therapy for metastatic prostate cancer. ¹⁷⁷Lu PSMA-617, along with the bone specific radiotherapeutic agent, ²²³RaCl₂ (Xofigo^®), are now commonly used in routine clinical care as a tertiary line of therapy for men with metastatic castrate resistant prostate cancer and for osseus metastatic disease respectively. While these radiopharmaceuticals are changing how metastatic prostate cancer is classified and treated, there is relatively little guidance to the practitioner and patient as to how best utilize these therapies, especially in con

SUBMITTER: Parent EE 

PROVIDER: S-EPMC9454920 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature